1. Home
  2. EDVA vs PFSA Comparison

EDVA vs PFSA Comparison

Compare EDVA & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EDVA

Endovia Health Sciences Inc. Common Stock

N/A

Current Price

$0.26

Market Cap

1.9M

ML Signal

N/A

PFSA

Profusa Inc.

HOLD

Current Price

$1.92

Market Cap

1.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EDVA
PFSA
Founded
N/A
2009
Country
United States
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
Medical/Dental Instruments
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9M
1.7M
IPO Year
2012
2021

Fundamental Metrics

Financial Performance
Metric
EDVA
PFSA
Price
$0.26
$1.92
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
236.1K
332.5K
Earning Date
N/A
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
32.30
N/A
EPS
N/A
N/A
Revenue
$73,066.00
$100,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.23
$0.05
52 Week High
$0.32
$28.32

Technical Indicators

Market Signals
Indicator
EDVA
PFSA
Relative Strength Index (RSI) 28.45 44.97
Support Level $0.23 $0.23
Resistance Level N/A $2.35
Average True Range (ATR) 0.03 0.36
MACD -0.00 -0.24
Stochastic Oscillator 29.19 15.74

Price Performance

Historical Comparison
EDVA
PFSA

About EDVA Endovia Health Sciences Inc. Common Stock

Endovia Health Sciences Inc is building a diversified cannabinoid health sciences platform through pharmaceutical innovation, strategic partnerships and disciplined execution. Endovia acquires, develops and commercializes differentiated cannabinoid health technologies across pharmaceutical, veterinary and consumer wellness markets. Endovia's product begins with CannEpil, a cannabinoid pharmaceutical asset, and extends into veterinary development and consumer wellness as the pipeline expands.

About PFSA Profusa Inc.

Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.

Share on Social Networks: